Log in

RGEN REPLIGEN CORP NASDAQ · United States

REPLIGEN CORP (RGEN) news RGEN convertible notes news

Latest REPLIGEN CORP news

We have not published a story on REPLIGEN CORP yet. When there is news, it will appear here.

REPLIGEN CORP annual financials

LineFY2025FY2024
Research and development$54.2 million$43.2 million
Net income (loss)$48.9 million-$25.5 million
Cash from operations$117.4 million$175.4 million
Cash and equivalents$566.0 million$757.4 million
Short-term investments$201.6 million$0

Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $727.0 million, plus short-term investments of $136.0 million, $863.0 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about REPLIGEN CORP

Has REPLIGEN CORP sold convertible notes?

Our latest story on this, dated Oct 30, 2026: "Repligen announces $1.0 billion private convertible notes transaction". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of REPLIGEN CORP?

REPLIGEN CORP trades under the ticker RGEN on NASDAQ.

Where is REPLIGEN CORP listed?

REPLIGEN CORP is listed on NASDAQ.

Which country or territory is REPLIGEN CORP listed under?

Our directory records REPLIGEN CORP under United States.

Does aibio.space cover REPLIGEN CORP?

aibio.space lists REPLIGEN CORP among 2,820 public biotech companies and publishes its news here as stories appear.

Is REPLIGEN CORP profitable?

REPLIGEN CORP reported net income of $48.9 million for the fiscal year ended Dec 31, 2025, and generated $117.4 million of cash from operations, per its annual report to the SEC.

How much does REPLIGEN CORP spend on research and development?

$54.2 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does REPLIGEN CORP have?

$863.0 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.

What is the latest REPLIGEN CORP (RGEN) stock news?

Our latest story on REPLIGEN CORP, dated Oct 30, 2026: "Repligen announces $1.0 billion private convertible notes transaction". The 0.25% notes due 2031 will be issued partly in exchange for 2028 notes and partly for cash, with a conversion price of approximately $226.37. Source.

How can I follow REPLIGEN CORP (RGEN) news?

Press Follow on this page to add REPLIGEN CORP to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming REPLIGEN CORP so far, in Debt Financing.

Investor discussion: REPLIGEN CORP

Members talk about REPLIGEN CORP (RGEN). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at REPLIGEN CORP, newest first. Each line links the filing it comes from.

  1. Mergers

    Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source

  2. Mergers

    Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,7.01,8.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:RGEN on TradingView.

Listing details

REPLIGEN CORP is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RGEN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
REPLIGEN CORP
Ticker
RGEN
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.